Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 3/20 | 0.37 |
| ▸ | NAMPT | P43490 | 2/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2774828 | 0.87 | GRIN2B (0.41) | GPR119USP30GRIN2BGRIN2CJAK3 | |
| SCHEMBL199926 | 0.87 | GRIN2B (0.41) | GPR119USP30GRIN2BGRIN2CJAK3 | |
| SCHEMBL1268184 | 0.87 | GRIN2B (0.41) | GPR119USP30GRIN2BGRIN2CJAK3 | |
| SCHEMBL4002726 | 0.80 | GRIN2B (0.38) | GPR119NAMPTGRIN2BGRIN2CJAK3 | |
| SCHEMBL15664940 | 0.78 | TSHR (0.43) | MAPK1GPR119KDM1AGRIN2BGRIN2C | |
| SCHEMBL27952441 | 0.78 | TSHR (0.43) | MAPK1GPR119KDM1AGRIN2BGRIN2C | |
| SCHEMBL27952440 | 0.78 | TSHR (0.43) | MAPK1GPR119KDM1AGRIN2BGRIN2C | |
| SCHEMBL3370511 | 0.78 | GRIN2B (0.41) | USP30GRIN2BGRIN2CJAK3 | |
| SCHEMBL2429525 | 0.78 | GRIN2B (0.41) | USP30GRIN2BGRIN2CJAK3 | |
| SCHEMBL2894585 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7807678-B2 | Peptidomimetics of biologically active metallopeptides | PALATIN TECHNOLOGIES, INC. (US) | 2010-10-05 | — | — | US | disclosed |
| US-7326707-B2 | Bicyclic melanocortin-specific compounds | PALATIN TECHNOLOGIES INCORPORATED (US) | 2008-02-05 | — | — | US | disclosed |
| US-20040171520-A1 | Peptidomimetics of biologically active metallopeptides | PALATIN TECHNOLOGIES, INC. | 2004-09-02 | — | — | US | disclosed |
| US-20040152134-A1 | Bicyclic melanocortin-specific compounds | PALATIN TECHNOLOGIES, INC. (US) | 2004-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171520-A1 | Peptidomimetics of biologically active metallopeptides | MC1R, MC4R, MC5R | MAPK1 3194/4885GPR119 493/4885USP30 4199/4885 |
| US-20040152134-A1 | Bicyclic melanocortin-specific compounds | MC3R, MC5R, MC2R | MAPK1 2316/4885GPR119 71/4885USP30 4649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.